Cite
HARVARD Citation
Zhou, C. et al. (n.d.). 129P Tislelizumab combined with bevacizumab plus nab-paclitaxel single-agent chemotherapy for advanced NSCLC after resistance to EGFR TKIs. Immuno-oncology technology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zhou, C. et al. (n.d.). 129P Tislelizumab combined with bevacizumab plus nab-paclitaxel single-agent chemotherapy for advanced NSCLC after resistance to EGFR TKIs. Immuno-oncology technology. p. . [Online].